-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Lucy Scientific Discovery (LSDI) Surges Pre-Market, Driven by Short Squeeze
Lucy Scientific Discovery (LSDI) Surges Pre-Market, Driven by Short Squeeze
Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a psychedelic products company, is experiencing a tremendous pre-market price surge of 62%, adding to the positive momentum of the day which already saw a 15% increase.
The market's heightened interest in LSDI reflects the growing fascination with psychedelic research and its potential impact on the biopharmaceutical industry.
LSDI's Remarkable Short Squeeze
Lucy Scientific Discovery Inc. (LSDI), a relatively new player in the market, has been on a volatile ride since its debut less than four months ago. However, the company is currently experiencing a significant pre-market price jump, reaching $1.73 per share, marking its highest level since March.
This sudden surge is being attributed to a short squeeze among traders, indicating that bears with short positions on LSDI stock are now rushing to cover their positions, resulting in increased demand and upward pressure on the stock price. The market is closely watching this development, anticipating further momentum for LSDI.
Lucy Scientific and TheraPsil Join Forces
In a significant development, Lucy Scientific Discovery Inc. (LSDI) has announced a partnership with TheraPsil, a leading non-profit organization advocating for legal access to psilocybin therapy in Canada.
This collaboration aims to advance medical psilocybin access and research, specifically targeting patients in need of end-of-life care and those with serious medical conditions.
The partnership not only facilitates patient access and supports compassionate care but also allows Lucy to introduce natural psilocybin products into the Canadian market, positioning the company as a pioneer in psychedelic compounds. This strategic move not only offers early consumer feedback but also strengthens Lucy's brand recognition in Canada and beyond.
Conclusion
LSDI stock has witnessed an impressive pre-market price surge, attributed to a short squeeze and fueled by growing interest in psychedelic research. The company's partnership with TheraPsil further solidifies its position in the industry, enabling access to psilocybin therapy and paving the way for the introduction of natural psilocybin products.
Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a psychedelic products company, is experiencing a tremendous pre-market price surge of 62%, adding to the positive momentum of the day which already saw a 15% increase.
迷幻產品公司Lucy Scientific Discovery Inc.(納斯達克股票代碼:LSDI)的盤前價格大幅上漲了62%,這加劇了當天已經上漲15%的積極勢頭。
The market's heightened interest in LSDI reflects the growing fascination with psychedelic research and its potential impact on the biopharmaceutical industry.
市場對LSDI的興趣日益濃厚,這反映了人們對迷幻研究及其對生物製藥行業的潛在影響的迷戀與日俱增。
LSDI's Remarkable Short Squeeze
LSDI 的驚人空頭擠壓
Lucy Scientific Discovery Inc. (LSDI), a relatively new player in the market, has been on a volatile ride since its debut less than four months ago. However, the company is currently experiencing a significant pre-market price jump, reaching $1.73 per share, marking its highest level since March.
Lucy Scientific Discovery Inc.(LSDI)是市場上相對較新的參與者,自不到四個月前首次亮相以來,一直處於動盪之中。但是,該公司目前正在經歷盤前價格的大幅上漲,達到每股1.73美元,這是自3月份以來的最高水平。
This sudden surge is being attributed to a short squeeze among traders, indicating that bears with short positions on LSDI stock are now rushing to cover their positions, resulting in increased demand and upward pressure on the stock price. The market is closely watching this development, anticipating further momentum for LSDI.
這種突然的飆升歸因於交易者的空頭擠壓,這表明在LSDI股票上空頭寸的空頭現在正急於填補頭寸,導致需求增加和股價面臨上行壓力。市場正在密切關注這一事態發展,預計LSDI將進一步發展勢頭。
Lucy Scientific and TheraPsil Join Forces
露西科學和TherapSil聯手
In a significant development, Lucy Scientific Discovery Inc. (LSDI) has announced a partnership with TheraPsil, a leading non-profit organization advocating for legal access to psilocybin therapy in Canada.
Lucy Scientific Discovery Inc.(LSDI)宣佈與TherapSil建立合作伙伴關係,TherapSil是一家倡導在加拿大合法獲得psilocybin療法的領先非營利組織,這是一個重大進展。
This collaboration aims to advance medical psilocybin access and research, specifically targeting patients in need of end-of-life care and those with serious medical conditions.
這項合作旨在促進醫用 psilocybin 的普及和研究,特別針對需要臨終護理和患有嚴重疾病的患者。
The partnership not only facilitates patient access and supports compassionate care but also allows Lucy to introduce natural psilocybin products into the Canadian market, positioning the company as a pioneer in psychedelic compounds. This strategic move not only offers early consumer feedback but also strengthens Lucy's brand recognition in Canada and beyond.
該合作伙伴關係不僅爲患者提供便利,支持富有同情心的護理,而且還使露西能夠將天然psilocybin產品引入加拿大市場,使該公司成爲迷幻化合物的先驅。這一戰略舉措不僅提供了早期的消費者反饋,還增強了露西在加拿大及其他地區的品牌知名度。
Conclusion
結論
LSDI stock has witnessed an impressive pre-market price surge, attributed to a short squeeze and fueled by growing interest in psychedelic research. The company's partnership with TheraPsil further solidifies its position in the industry, enabling access to psilocybin therapy and paving the way for the introduction of natural psilocybin products.
LSDI股票見證了令人印象深刻的盤前價格飆升,這歸因於空頭擠壓,並受對迷幻研究的興趣與日俱增。該公司與TherapSil的合作進一步鞏固了其在行業中的地位,使人們能夠獲得psilocybin療法,併爲引入天然psilocybin產品鋪平了道路。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧